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Drug deliveryAbstract Nanovesicles (NVs) represent a novel transporter for cell signals to modify functions of
target cells. Therefore, NVs play many roles in both physiological and pathological processes. This
report highlights biogenesis, composition and biological roles of erythrocytes derived nanovesicles
(EDNVs). Furthermore, we address utilization of EDNVs as novel drug delivery cargo as well as
therapeutic target. EDNVs are lipid bilayer vesicles rich in phospholipids, proteins, lipid raft,
and hemoglobin. In vivo EDNVs biogenesis is triggered by an increase of intracellular calcium
levels, ATP depletion and under effect of oxidative stress conditions. However, in vitro production
of EDNVs can be achieved via hypotonic treatment and extrusion of erythrocyte. NVs can be used
as biomarkers for diagnosis, monitoring of therapy and drug delivery system. Many therapeutic
agents are suggested to decrease NVs biogenesis.
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Cells continuously secrete a large number of small molecules,
macromolecules and nanovesicles into the extracellular space
(Vlassov et al., 2012). Nanovesicles (NVs) are submicron
membrane-coated vesicles of diameter up to 1000 nm, in which
they are released from all cell types and contain cellular compo-
nents of their parent’s cell (Vlassov et al., 2012). Exosomes and
microvesicles (MVs) are collectively known as extracellular vesi-
cles (EVs), and they have an aqueous core surrounded by a lipid
bilayer membrane (Kastelowitz and Yin, 2014). EVs are consid-
ered as a new class of signalmediators, which allow the transport
of nucleic acids, proteins, lipids and secondmessengers (Vlassov
et al., 2012; Kastelowitz and Yin, 2014). EVs play signiﬁcant
roles in genetic transfer, cytokine release, angiogenesis, transfer
of cell receptors, and proteinase release (Kastelowitz and Yin,
2014). Under activation, growth, apoptosis, senescence, shear-
ing stress, oxidative stress and injury, cells release excessive
amount of EVs (Antwi-Baffour et al., 2013A,B).
Most of cells including endothelial cells, immune cells, can-
cer cells, hematopoietic cells, platelets, and erythrocytes are
able to secret EVs (Fais et al., 2013). EVs are formed by bud-
ding of the plasma membrane through the dynamic redistribu-
tion of phospholipids (Lutz and Bogdanova, 2013). MVs and
exosomes are differing in the biogenesis, size, surface markers,
and biological roles (Fais et al., 2013). MVs are plasma
membrane-derived vesicles with size range between 100 nm
and 1000 nm. During their formation, MVs retain surface
molecules from parent’s cell as well as part of their cytosolic
content (Loyer et al., 2014).
On the contrary, exosomes have size up to 150 nm and are
derived from a cascade of the fusion between early and late
endosomes, lysosomes, and others depending on their cellular
source (Fais et al., 2013; Loyer et al., 2014). The fusion of mul-
tivesicular bodies with the plasma membrane allows the releasePlease cite this article in press as: Harisa, G.I. et al., Erythrocyte nanovesicles: Bioge
(2015), http://dx.doi.org/10.1016/j.jsps.2015.06.010of exosomes into the extracellular space. Exosomes are mem-
branous structures with a lipid bilayer rich in phospholipids,
proteins, cholesterol, ceramide, and sphingolipids (Vlassov
et al., 2012). EVs can circulate in the vascular network, where
they can evade phagocytosis as well as they can participate in
autocrine, paracrine and endocrine signaling (Prati et al.,
2010).
In healthy humans, circulating EVs are mainly derived
from platelets and to a lesser extent leukocyte and endothelial
cells. An increase of EVs biogenesis has been demonstrated in
physiological and pathological conditions (Lovren and Verma,
2013). The vascular endothelium is one of the primary targets
of circulating EVs; they contribute to the regulation of
endothelial cell functions, coagulation and inﬂammation
(Lovren and Verma, 2013). However, abnormal biogenesis of
EVs leads to endothelial dysfunction and development of
cardiovascular diseases (Lovren and Verma, 2013).
The biogenesis of EVs is an inherent property of the
erythrocyte plasma membrane. In healthy individuals, erythro-
cytes derived nanovesicles (EDNVs) are present at basal levels
(Jank and Salzer, 2011). However, aging, high intracellular
calcium levels and oxidative stress are triggers of erythrocytes
vesiculation and release of EVs. Oxidized erythrocytes (Oxi-Ery)
released EVs rich in oxidized proteins, lipid peroxides, choles-
terol and other oxidized substances. Oxi-Ery and EDNVs are
engulfed by macrophages and smooth muscle cells resulted in
foam cells formation, and this induced endothelial dysfunction
and enhanced atherosclerotic process (Blum, 2009; Tziakas
et al., 2010). An increase in EVs release was observed in hyper-
tension, thrombocytopenia, multiple sclerosis, sickle cell ane-
mia, diabetes, and atherosclerosis (Antwi-Baffour et al.,
2013A,B).
Biogenesis, secretion mechanisms as well as biological roles
of EVs have not been fully reported. Furthermore, their phys-
iological and pathological roles are still a matter for research.nesis, biological roles and therapeutic approach. Saudi Pharmaceutical Journal
Figure 1 General mechanism of biogenesis and release of extracellular vesicles (EVs), MVs bud directly from the plasma membrane,
whereas exosomes are formed by budding of early endosomes.
Erythrocytes nanovesicles as therapeutic target 3Therefore, this report overviews biogenesis, beneﬁcial and
detrimental effects of EVs focus on EDNVs as new modulators
in vascular disease. We hope that the present review will
increase the understanding of EV biology.
2. EVs biogenesis
Under resting cellular conditions, phospholipids in the bilayer
of plasma membrane are asymmetrically distributed.
Phosphatidylcholine (PC) and sphingomyelin are mostly
present in the outer leaﬂet (Larson et al., 2012). However, phos-
phatidylserine (PS), phosphatidylethanolamine and phos-
phatidylinositides are mainly present in the inner layer. This
dynamic distribution of phospholipids is maintained by
enzymes such as ATPases, scramblases, and ﬂoppases
(Larson et al., 2012). Transient or irreversible redistribution
of phospholipid(s) across the membrane bilayer has been
shown to play important roles in cellular events (Larson
et al., 2012). For example exposure of cells to oxidative stress,
infection, cell signals, apoptosis and other stimuli resulted in
EVs biogenesis (Prati et al., 2010). Calcium ions are key players
in EVs biogenesis due to inactivation of ﬂippase. However cal-
cium ions activate ﬂoppase, scramblase, calpain and gelsolin.
Calpain hydrolyzes actin binding proteins that decrease the
association of actin with membranes glycoproteins. However,
gelsolin is involving in the cleavage of the actin capping pro-
teins. These events are inducing loss of phospholipid asymme-
try and protein anchorage to the cytoskeleton is disrupted,
resultant in membrane budding and EVs release (Burnier
et al., 2009). EVs isolated from blood are rich in phosphatidyl-
choline, sphingomyelin and minor quantities of other phospho-
lipids (Burnier et al., 2009). EVs are characterized by PS
exposed on their outer surface and other component of the par-
ent cell. Fig. 1 shows biogenesis and release of exosome and
MVs; it clears that MVs bud directly from the plasma mem-
brane, whereas exosomes are formed by budding of early endo-
somes. Calcium ions are key player in EVs biogenesis.3. Biological roles of EVs
In many biological systems, EVs are considered as important
mediators of cell–cell communication to underpinPlease cite this article in press as: Harisa, G.I. et al., Erythrocyte nanovesicles: Bioge
(2015), http://dx.doi.org/10.1016/j.jsps.2015.06.010physiological function (Lee et al., 2012). Under physiological
conditions, EVs are released from various cell types to act as
cellular messenger (Prati et al., 2010; Lamichhane et al.,
2015). EVs transfer the bioactive molecules to target cells;
therefore, EVs can modulate various biological processes such
as angiogenesis, growth, cell differentiation, immune func-
tions, stress response, and senescence (Prati et al., 2010;
Lamichhane et al., 2015).
The cellular uptake machinery of EV may depend on pro-
teins and glycoproteins found on the surface of both the vesicle
and the target cell (Mulcahy et al., 2014). Moreover, the pres-
ence of external PS is a key determinant of the interaction of
EVs with target cells; also the oxidized lipids may play the
same role (Loyer et al., 2014). Cellular entrance of EVs is
mediated by clathrin-dependent endocytosis, caveolin-
mediated uptake, lipid raft-mediated internalization and
phagocytosis (Mulcahy et al., 2014).
EVs are involved in inﬂammation and homeostasis, blood
coagulation and apoptosis (Herring et al., 2013). In the ner-
vous system, EVs transmit the information in the form of pro-
teins to facilitate neural circuit function.
On contrary, EVs have several detrimental effects such as
enhanced viral infection, neurodegeneration and tumorigenesis
(Lee et al., 2012). Abnormal level of circulating EVs was doc-
umented in varieties of human diseases such as atherosclerosis,
acute myocardial infarction, diabetes, hypertension, acute
ischemic stroke, hyperlipidemia, and metabolic syndrome
(Herring et al., 2013; Loyer et al., 2014).
4. Erythrocytes-derived vesicles(EDNVs)
Normal erythrocytes have ﬂexible biconcave shape with a cell
diameter microsize of 5–7 lm and a thickness of 2 lm. The
main functions of erythrocytes are transport of oxygen and
carbon dioxide, and release of adenosine triphosphate (ATP)
and nitric oxide (NO). Moreover, erythrocytes carry signiﬁcant
enzymes and molecules involved in L-arginine/NO metabolic
pathway (Porro et al., 2014).
Erythrocytes are the major vesicle-secreting cells in the cir-
culating blood (Donadee et al., 2011), during their life span,
and erythrocytes lose approximately 20 % of their hemoglobin
and membrane through vesiculation (Alaarg et al., 2013). The
erythrocyte vesicles are known as microvesicles, exovesicles,nesis, biological roles and therapeutic approach. Saudi Pharmaceutical Journal
Figure 2 Proposed mechanism of oxidative stress induced erythrocyte vesiculation. EDNVs biogenesis triggered calcium concentrations
that activate calpain, scramblase, and ﬂippase.
4 G.I. Harisa et al.ectosomes, nanovesicles and microparticles (Jank and Salzer,
2011). Erythrocytes-derived nanovesicles (EDNVs) have aver-
age size approximately 100–200 nm with a lipid bilayer rich in
phospholipids, proteins, cholesterol, lipid raft, hemoglobin
and acetylcholinesterase (Jank and Salzer, 2011; Lutz and
Bogdanova, 2013).
EDNVs biogenesis has been described as a part of erythro-
cytes senescence and also proposed as a part of an apoptosis-
like process (eryptosis) in these cells. The release of EDNVs
plays a protective role that allows erythrocytes to clear away
dangerous molecules and prevent their early removal from
circulation (Tissot et al., 2013). Therefore, EDNVs act as a
self-protective mechanism for removal of dangerous molecules
formed during erythrocytes life span (Willekens et al., 2008).
EDNVs were demonstrated in ischemia, shearing stress, car-
diovascular diseases, hematological disorders and diabetes
(Antwi-Baffour et al., 2013B).
An increase of intracellular calcium levels leads to disrup-
tion membrane asymmetry with concomitant biogenesis of
EDNVs (Jank and Salzer, 2011). Additionally, depletion of
ATP depletion and exposure to membranotropic and hemoly-
tic agents trigger NVs release from erythrocytes (Donadee
et al., 2011; Lutz and Bogdanova, 2013). As well, morpholog-
ical alterations, storage conditions, arachidonic acid, lysophos-
phatidic acid, and loss of deformability propagate erythrocytes
vesiculation (Chung et al., 2007).
Oxidative stress and heavy metals exposure potentiate NVs
shedding from erythrocytes due to depletion of antioxidant
defense (Jank and Salzer, 2011; Noh et al., 2010). The inhibi-
tion of EDNVs biogenesis by antioxidants conﬁrmed role of
oxidative stress in stimulation of EVs production (Herring
et al., 2013). Erythrocytes vesiculation is associated with pro-
tein oxidation, and lipid peroxidation leading to a loss ofPlease cite this article in press as: Harisa, G.I. et al., Erythrocyte nanovesicles: Bioge
(2015), http://dx.doi.org/10.1016/j.jsps.2015.06.010deformability (Herring et al., 2013). Similarly in many cells,
EDNVs biogenesis triggered calcium concentrations that acti-
vate calpain, scramblase, and ﬂippase (Larson et al., 2012).
4.1. Mechanisms of EDNVs biogenesis
Three mechanisms have been proposed to explain EDNVs bio-
genesis, the eryptosis model, the band 3 clustering and oxida-
tive stress. The eryptosis mechanism is similar to apoptosis of
nucleated cells in response to various stresses but applied to
erythrocytes (Tissot et al., 2013). Thus, a rise of ionic calcium
inﬂux through alteration of nonspeciﬁc cation channels leads
to activation of calpain, scramblase and ﬂoppase; however,
ﬂippase was inactivated (Burnier et al., 2009). This resulted
in disruption of phospholipid asymmetry and release of NVs.
In band 3 clustering mechanism hemoglobin oxidation leads
to hemichrome formation, followed by aggregation of band
3 multimers, degradation of cytoskeletal proteins and modiﬁ-
cation of band 3 phosphorylation (Tissot et al., 2013). In
oxidative stress hypothesis, reactive species induce binding of
hemoglobin to band 3, activation of calcium channels, and
phosphorylation of proteins and aggregation of band 3
(Tissot et al., 2013). This hypothesis of erythrocytes vesicula-
tion has been reinforced by the postulation of a study demon-
strated that antioxidants addition inhibits NVs biogenesis
(Stowell et al., 2013). Fig. 2 shows proposed mechanism of
oxidative stress induced erythrocyte vesiculation.5. Biological roles of EDNVs
In the past, EVs were considered as a garbage basket for
removing unwanted materials as an integrated machinery ofnesis, biological roles and therapeutic approach. Saudi Pharmaceutical Journal
Erythrocytes nanovesicles as therapeutic target 5the lysosomal system. However, more recent data support the
role of NVs in cellular homeostasis (Fais et al., 2013).
Various studies have suggested the importance of NVs in
numerous cellular processes (Jank and Salzer, 2011).
EDNVs are produced as a machinery to prevent premature
erythrocyte removal by reticuloendothelial system.
Therefore, these NVs protect erythrocytes via removal of
complement attack complex, band 3 antigens, nonfunctional
hemoglobin and other unwanted membrane-associated ele-
ments (Herring et al., 2013).
5.1. EDNVs and oxidative stress
Normally, erythrocytes are provided with antioxidant mole-
cules such as glutathione, thioredoxin, ascorbic acid and vita-
min E. Furthermore, they contain superoxide dismutase,
catalase, glutathione peroxidase, thioredoxin reductase,
glutathione reductase, and methemoglobin reductase (Kennett
and Kuchel, 2006; Minetti et al., 2007). Therefore, functional
erythrocytes act as vascular guardian by scavenging reactive
oxygen species (ROS) generated in itself, circulated blood,
and vascular cells (Minetti et al., 2007). The decrease of
erythrocytes antioxidant capacity resulted in oxidative stress
and NO inactivation. In such cases, erythrocytes are labeled
as key player in many diseases particularly cardiovascular dis-
ease (Eligini et al., 2013).
It has been reported that EDNVs are one of the priming
causes of respiratory burst (Jank and Salzer, 2011), which is
characterized by neutrophils activation with production of
excessive amount of ROS. This is attributed to NVs having
NADP oxidase subunits (Loyer et al., 2014). Moreover,
Gaceb et al. (2014), reported that EVs upregulate NADPH-
oxidase expression. Respiratory burst causes plethora of
changes in cytoskeleton and cell membrane asymmetry
resulted in formation of Oxi-ERY (Minetti et al., 2007). Oxi-
ERY is rigid and undergoes hemolysis releasing cholesterol,
lipids peroxidation product, aggregated protein and iron. All
of them are potent stimulator of vascular cellular damage
(Willekens et al., 2008). Therefore, Oxi-ERY and EDNVs
act as dangerous bullets to vascular cells and trigger the dam-
aging process (Minetti et al., 2007).
5.2. EDNVs and inﬂammation
EVs releases stimulate cell–cell interaction, adhesion molecule
expression, cytokine release and increased macrophage differ-
entiation (Loyer et al., 2014). The main components of
erythrocyte membrane are phospholipids and cholesterol
(Tziakas et al., 2010). Erythrocyte membranes are richer in
cholesterol than other cell in the body; subsequently, EDNVs
are enriched in cholesterol, lipid raft, membrane proteins and
hemoproteins (Lutz and Bogdanova, 2013). The crystallization
of cholesterol obtained from erythrocyte membrane may
induce inﬂammatory reactions; furthermore, iron can act as
a catalyst for ROS production (Minetti et al., 2007), that pro-
duce tissue damage and initiate extra inﬂammatory reactions
(Moreno et al., 2006). Moreover, hemoglobin released from
erythrocyte’s hemolysis activates the pro-inﬂammatory tran-
scription factor (Moreno et al., 2006). Phospholipase A2
hydrolyzes EDNVs phospholipids resulted in production of
inﬂammatory mediators (Alaarg et al., 2013). Also, NVsPlease cite this article in press as: Harisa, G.I. et al., Erythrocyte nanovesicles: Bioge
(2015), http://dx.doi.org/10.1016/j.jsps.2015.06.010activate neutrophils that release myeloperoxidase as main
source of ROS (Buesing et al., 2011). Altogether propagate
vascular inﬂammation that accelerates the development of
coronary heart diseases.
5.3. EDNVs and NO homeostasis
NVs might exert beneﬁcial or deleterious effects for the vascu-
lar wall depending on their cellular origin (Puddu et al., 2010).
Additionally, Gaceb et al. (2014), reported that EVs have con-
tradictory effects on NO biology, and EVs decrease NO
bioavailability by reducing the activity of endothelial NO syn-
thase. However, EVs induced up-regulation of inducible NO
synthase resulting in an over production of NO. Therefore,
EVs can induce endothelial dysfunction by enhancement of
ROS production that reduces NO bioavailability (Herring
et al., 2013; Franc¸a et al., 2015; Burnier et al., 2009).
Similarly, it has been demonstrated that NVs disrupt NO
homeostasis by oxidative stress mediated mechanism.
Moreover, EDNVs are hemoglobin containing vesicles or
hemoglobin devoid of vesicles, both vesicles enhanced NO
inactivation (Donadee et al., 2011). It has been reported that,
EDNVs scavenge NO faster than intact erythrocytes (Herring
et al., 2013). Therefore, EDNVs are vasoconstrictors,
increased erythrocyte adhesion, enhanced endothelial damage
and caused vaso-occlusions (Camus et al., 2012).
Erythrocytes vesiculation was associated with releasing of
arginase-1 and hemoglobin into blood stream (Donadee
et al., 2011; Yang et al., 2013). Release of erythrocyte’s argi-
nase was associated with lowered blood NO levels that induced
erythrocyte dysfunction and endothelial damage (Kim et al.,
2013). Beside erythrocyte’s arginase, their dimethylarginines
and cationic amino transporter are important regulators of
NO (Yokoro et al., 2012). Asymmetric dimethylarginine com-
petes with L-arginine transport; however, symmetric dimethy-
larginine interferes with L-arginine into the cells (Davids et al.,
2012; Eligini et al., 2013).
5.4. EDNVs and thrombosis
EDNVs have procoagulant activity by participation in blood
clotting process and enhancing thrombus formation (Chung
et al., 2007). These vesicles accelerate the coagulation cascade
via conversion of prothrombin into thrombin (Martinez et al.,
2005). The presence of PS on the surface of NVs provides a site
for the assembly of the prothrombinase leading to formation
of thrombin clot. Additionally, NVs can enhance clotting by
inducing expression of clotting factors (Distler et al., 2005).
Adhesion of PS-expressing EDNVs to endothelial cells
induced vaso-occlusion. Moreover, PS-exposed NVs provide
sites for adhesion of platelets and neutrophils localized at the
subendothelium. Taken together, PS-exposed EDNVs are
new players in the development of thrombosis that is a risk fac-
tor in cardiovascular disease progression (Noh et al., 2010).
5.5. EDNVs and foam cell formation
Erythrocyte life span is limited by senescence with subsequent
clearance of the aged erythrocytes, prior to senescence; they
undergo suicidal death or eryptosis (Lang et al., 2012).
Phospholipid asymmetry is maintained throughout the lifenesis, biological roles and therapeutic approach. Saudi Pharmaceutical Journal
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PS was exposed on their outer surface and acted as a marker
for macrophages to engulf aged erythrocytes; therefore, PS
acts as signal for eryptosis and erythrophagocytosis
(Kleinegris et al., 2012). Eryptosis shares other hallmarks of
apoptosis, such as cell shrinkage, cell membrane blebbing
and scrambling leading to PS exposure at the cell surface
(Lang et al., 2012). EDNVs-PS acts as an ‘‘eat me’’ marker
for macrophages for removing damaged erythrocytes
(Willekens et al., 2008). Therefore, reticuloendothelial system
removes the PS-exposing nanovesicles instead of their parent’s
erythrocyte (Willekens et al., 2008).
Under oxidative stress erythrocytes are prone to subsequent
vesiculation and production of NVs (Blum, 2009). The surface
of Oxi-Ery is ﬂagged by PS exposure on the outer leaﬂets.
Therefore, they are recognized by macrophage scavenger
receptors (Tziakas et al., 2010). This evokes foam cell forma-
tion (Schrijvers et al., 2007) and stimulates smooth muscle cell
migration, which contributes to the progression of atheroscle-
rosis (Schrijvers et al., 2007). The erythrocyte membrane is
richer in cholesterol than other cells; therefore, intracellular
free cholesterol accumulation is increased that triggers foam
cells formation (Tziakas et al., 2010). Moreover, NVs stimulate
inﬂammatory responses and growth of necrotic core (Loyer
et al., 2014). Consequently, NVs contribute to the progression
of atherosclerosis (Herring et al., 2013).
6. Isolation and detection of EVs
EVs separation is a major focus in the ﬁeld of EVs research.
The isolation processes of EVs include numerous sequential
centrifugation steps with increasing centrifugal force. Thus size
and density properties of EVs are used for the separation of
EVs from other blood components. Initially, low-speed steps
(300–500g) are applied to remove cells (Revenfeld et al.,
2014). This is followed by higher speeds in the range of
10,000–20,000g, to remove cellular debris and to isolate
larger EVs > 100 nm. Finally, one or more ultracentrifugation
steps are applied to pellet the smallest EVs, using centrifugal
forces in the range of 100,000–200,000g (Revenfeld et al.,
2014).
It is also possible to combine the ultracentrifugation with a
density gradient, or afﬁnity puriﬁcation. The choice of the iso-
lation procedure may have a considerable effect on the
downstream analyses of EVs. In addition to the isolation,
the pre-analytical procedures such as choice of anticoagulant,
processing temperature and storage before analysis may
affect detection and characterization of NVs (Revenfeld
et al., 2014).
Characterization of NVs with regard to size, morphology,
concentration, biochemical composition and cellular origin
has been documented (Herring et al., 2013). NVs surface
markers allow identiﬁcation and quantitation, although mar-
ker density must be sufﬁcient to allow detection. Moreover,
biochemical determinations of molecular components can
allow enumeration in isolated EVs preparations (Pisetsky
et al., 2012).
Assays of functional activity have also been used for certain
NVs subpopulations. The presence of nucleic acids provides
another means to measure NVs using dyes that interact with
DNA and RNA. The use of nucleic acid-binding dyes canPlease cite this article in press as: Harisa, G.I. et al., Erythrocyte nanovesicles: Bioge
(2015), http://dx.doi.org/10.1016/j.jsps.2015.06.010provide information on the cell of origin of EVs (Pisetsky
et al., 2012). Furthermore, EVs can be characterized by the
detection of the different cell surface antigens. These antigens
reﬂect their origin and activation method (Burnier et al., 2009).
Also, characterization of EVs requires complementary bio-
chemical, mass spectrometry, and imaging techniques
(Raposo and Stoorvogel, 2013). Isolation methods, centrifuga-
tion protocols, time and temperature between phlebotomy and
initial centrifugation, thaw and freezing, reagent compositions,
instrument settings and calibration affect EVs analysis
(Jayachandran et al., 2012).
The common technologies widely applied for the detection
of EVs include electron microscopy, ﬂow cytometry, dynamic
light scattering, and nanoparticle tracking analysis
(Kastelowitz and Yin, 2014). The frequently used techniques
in EVs detection are ﬂow cytometry analysis, and enzyme-
linked immunoassays. As well, ﬂuorescence-based antibody
array system can rapidly identify the cell origin of EVs.
Despite several techniques are used in EVS characterization,
the measurement of NVs still has standardization problems
(Puddu et al., 2010).7. Application of NVs
NVs are normally released from the organs into the blood
stream and can be detected in the peripheral blood.
Moreover, they can be detected in the urine and other body
ﬂuids (Fais et al., 2013). The circulating basal levels of EVs
can be found in the blood of healthy individuals. However,
an increase in their release may be considered as biomarker
of biological changes; hence, they have possible diagnostic
values (Antwi-Baffour et al., 2013A). Although some of these
NVs populations occur in the blood of healthy individuals
and patients, there are obvious changes in number, cellular
origin, and composition in various disease states (Fais et al.,
2013).7.1. NVs as biomarkers for diseases
The release of NVs has been shown from endothelial cells, vas-
cular smooth muscle cells, platelets, white blood cells, erythro-
cytes, neurons and cancer cells (Vanwijk et al., 2003). The
concentration and composition of NVs depend upon their
cellular origin and the stimuli that trigger their production
(Jayachandran et al., 2012). Therefore, circulating NVs can
be used as sensitive and speciﬁc biomarkers for diseases.
NVs have been investigated for prognosis in cardiovascular
diseases, paroxysmal nocturnal hemoglobinuria, heparin
induced thrombocytopenia, sickle cell disease and sepsis
(Jayachandran et al., 2012). Particularly, an increase of circu-
lating NVs originating from blood cells was demonstrated as
marker for atherosclerosis exacerbation (Cocucci et al.,
2009). Furthermore, NVs were used as biomarker for neurode-
generative disorders, diabetes, rheumatic diseases, cancer and
other diseases (Pap et al., 2009; Cocucci et al., 2009). NVs con-
tain cytokines that can be used as indicator for inﬂammatory
response (Distler et al., 2005). Increased level of EVs was doc-
umented in patients with neurological diseases (Colombo
et al., 2012).nesis, biological roles and therapeutic approach. Saudi Pharmaceutical Journal
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7.2.1. NVs as drug delivery cargo
EVs are promising biological drug delivery nano-carriers, and
they could overcome restrictions of synthetic nanocarriers (Lai
et al., 2013). They are well tolerated and could be delivering
hydrophilic, hydrophobic drugs as well as biopharmaceuticals;
therefore, EVs are suitable for the development of drug deliv-
ery cargo (Lai et al., 2013). EVs have ability to permeate
plasma membrane of target cells, have an intrinsic ability to
home target tissues, and their membrane can be amenable to
improve speciﬁc cell targeting (Lai et al., 2013).
Consequently, NVs can deliver various drugs to speciﬁc tis-
sues, thereby reducing therapeutic doses and decreasing side
effects (Sun et al., 2010). EVs are vectors which transfer ther-
apeutic agents that maintain cell homeostasis, cell repair, and
cardioprotective drugs. Hence, EVs have beneﬁcial effects in
the ﬁeld of cardiovascular medicine and regenerative therapy
(Fleury et al., 2014). Additionally, drug loaded NVs can be
across blood–brain barrier to deliver their cargo to neurons
(Lakhal and Wood, 2011). These biological carriers overcom-
ing immunogenicity were associated with liposomes, nanopar-
ticles and viral vectors (Fleury et al., 2014).
By mimicking EVs, artiﬁcial NVs are constructed from
phospholipid precursors to form phospholipid bilayer mem-
branous nanovesicles. They have amphipathic and biocompat-
ibility properties. Artiﬁcial NVs are member of smart drug
delivery systems, improve solubility, prolonged action, and
reduced drug toxicity and increase cellular accumulation of
drugs (Fleury et al., 2014). Despite, artiﬁcial NVs are attractive
tools for drug delivery; they still have some biocompatibility
problems such opsonization and recognition by immune sys-
tem as foreign bodies (Lai et al., 2013; Elbialy and Mady,
2015). Therefore, they could be coated with hydrophilic poly-
mers to reduce their recognition by opsonins and clearance byFigure 3 Erythrocyte and erythrocyte derived nanovesicles (EDNV)
delivery system erythrocyte is used for sustained release, targeting, bio
targeting and EDNV stealth vehicle. Preswelling is performed using h
hypertonic NaCl solution.
Please cite this article in press as: Harisa, G.I. et al., Erythrocyte nanovesicles: Bioge
(2015), http://dx.doi.org/10.1016/j.jsps.2015.06.010recto-endothelial system (Lai et al., 2013). This approach is
partially solving the problem of nanoparticle opsonization.
The production of biomimics of nanoparticle stealth is novel
challenge in the ﬁeld of drug delivery. EDNVs-coated
nanoparticles for long-circulating cargo delivery may resolve
the problem of nanoparticles opsonization (Hu et al., 2011).
7.2.2. EDNVs as nanoparticles stealth
In vivo administration of nanoparticles larger than 100 nm is
opsonized and quickly eliminated from the circulation via
the reticuloendothelial system (Cole et al., 2011). Therefore,
production of camouﬂaged nanoparticles for long-circulating
cargo delivery may resolve the problem of nanoparticles
opsonization (Hu et al., 2011).
Erythrosomes are EDNVs, and they are biodegradable
vesicles and non-immunogenic in autologous administration
(Hu et al., 2011; Gupta et al., 2014). Nanoerythrosomes are
prepared by extrusion of erythrocyte ghosts through ﬁlters of
deﬁned pore size. They are used as a novel drug delivery sys-
tem and used as nanoparticles stealth to minimize nanoparti-
cles clearance (Hu et al., 2011; Gupta et al., 2014).
Nanoparticles stealth can be achieved using bioinspired
nanoparticles with biomimetic camouﬂage coating such ery-
throcytes, erythrocyte ghosts and EDNVs (Balmert and little,
2012; Noble et al., 2014). These biomimetic cargos have
tremendous potential in drug delivery applications, as they
provide the opportunity to actively inhibit the rapid immune
clearance of their therapeutic cargo, thereby improving drug
pharmacokinetics and therapeutic efﬁcacy (Hu et al., 2013).
Fig. 3 represents role of erythrocytes and EDNVs as drug
delivery system and nanoparticle stealth.
Also, these cargos can be delivered to speciﬁc tissues such
as intravascular drug delivery, liver, spleen, lungs and bone
marrow as well as selective tumor targeting (Muzykantov,
2010; Noble et al., 2014).as drug delivery systems and as stealth for nanoparticles. As drug
reactor and biomimics stealth. However, EDNV is mainly used as
ypotonic NaCl solution, whereas resealing step is achieved using
nesis, biological roles and therapeutic approach. Saudi Pharmaceutical Journal
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EVs are double weapon that has both valuable and unfavor-
able effects on the biological systems. Disruption of NVs bio-
genesis may elicit deleterious effects on cellular components.
Consequently, approaches that minimize NVs biogenesis could
represent novel therapeutic approach (Lovren and Verma,
2013). The design of NVs modulating therapy is based on
inhibiting EVs biogenesis, inhibiting their cellular uptake, or
inhibiting their active components (EL Andaloussi et al.,
2013). Consequently, inhibition of ceramide biosynthesis
decreases EVs biogenesis as well as GTPases inhibitors may
inhibit EVs release. However, NVs cellular entrance is prohib-
ited by blocking PS receptors and protein receptors on the
receipt cells (EL Andaloussi et al., 2013; Mulcahy et al.,
2014). Moreover, Mulcahy et al. (2014), listed several agents
that inhibit EVs cellular entry such as heparin, chlorpro-
mazine, amiloride, annexin-V, proton pump inhibitor and
other agents (Mulcahy et al., 2014).
Statins have hypocholesterolemic effect and pleiotropic
effects such as antioxidant, anti-proliferative, anti-thrombotic
effects, inhibition of NADPH oxidase activity and inhibition
of G-protein lipidation (Tramontano et al., 2004). Inhibition
of G-protein signaling by statins was proposed as EVs mecha-
nism (Loirand et al., 2013). As well statins inhibit lipid raft
mediated endocytosis (Mulcahy et al., 2014).
It is well demonstrated that an increases of intracellular cal-
cium, ROS, and apoptotic events are common causes in NVs
production by most cells (Prati et al., 2010; Burnier et al.,
2009). In this regard, calcium antagonists and ROS scavengers
may elicit inhibitory effect on cellular vesiculation. Calcium
channel blockers are an example of agent that attenuates
EVs biogenesis (Lovren and Verma, 2013). Moreover, therapy
by renin angiotensin inhibitor led to a decrease in EVs levelPlease cite this article in press as: Harisa, G.I. et al., Erythrocyte nanovesicles: Bioge
(2015), http://dx.doi.org/10.1016/j.jsps.2015.06.010(Franc¸a et al., 2015). As well, lowering of oxidative stress low-
ered EVs level (Lovren and Verma, 2013). In this regard,
Herring et al. (2013) reported that antioxidant therapy inhibits
the NVs formation. Furthermore, reduction in oxidative stress
resulted in decline of NVs biogenesis (Franc¸a et al., 2015).
Likewise, Stowell et al. (2013) demonstrated a signiﬁcant
decrease in EVs production by the addition of antioxidants
to erythrocytes. Fig. 4 displays the possible effect of therapeu-
tic agents on NVs biogenesis.
It is important to emphasize that inhibition of EVs biogen-
esis could result in undesirable effects because EVs and their
active components are important for the regulation of normal
biological processes and other core cellular functions (EL
Andaloussi et al., 2013).
8. Conclusion
EVs transmit biological signals that can implicate in numerous
physiological and pathological processes. EVs are released in
body ﬂuids and can be used as potential biomarkers for diag-
nosis, prognosis and monitoring of the therapeutic efﬁcacy.
EDNVs can mediate harmful effects such as thrombosis,
inﬂammation, endothelial dysfunction atherosclerosis and
vaso-occlusion. Calcium antagonist, antioxidant and statins
are proposed agents that may modulate EVs biogenesis.
Despite EDNVs appear as new culprit that affects vascular
functions, they can be used as smart drug delivery tool.
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